Ibrutinib alleviates LPS-induced neuroinflammation and synaptic defects in a mouse model of depression

• Published in: Brain, behavior, and immunity behavior, and immunity, 2021-02, Vol.92, p.10-24
• Main Authors: Li, Weifen, Ali, Tahir, He, Kaiwu, Liu, Zizhen, Shah, Fawad Ali, Ren, Qingguo, Liu, Yan, Jiang, Anlong, Li, Shupeng
• Format: Article
• Language: English
• Subjects: Depression; Ibrutinib; Inflammasome; Neuroinflammation; Synaptic defects
• ISSN: 0889-1591; 1090-2139
• DOI: 10.1016/j.bbi.2020.11.008

•Ibrutinib treatment reduced LPS induced depressive-like behaviors.•Ibrutinib prevents neuroinflammation via NF-kB signaling inhibition.•Ibrutinib treatments altered Nrf2, HO-1, and SOD2 expression under stress conditions.•Ibrutinib inhibited inflammasome activation via NLRP3/P38/Caspase-1 signaling.•Ibrutinib administration reduced synaptogenesis defects. Previous studies have demonstrated a close association between an altered immune system and major depressive disorders, and inhibition of neuroinflammation may represent an alternative mechanism to treat depression. Recently, the anti-inflammatory activity of ibrutinib has been reported. However, the effect of ibrutinib on neuroinflammation-induced depression and its underlying mechanism has not been comprehensively studied. Therefore, we aimed to elucidate the potential anti-depressive role and mechanism of ibrutinib against neuroinflammation-induced depression and synaptic defects. Our results showed that ibrutinib treatment significantly reduced lipopolysaccharide (LPS)-induced depressive-like behaviors and neuroinflammation via inhibiting NF-kB activation, decreasing proinflammatory cytokine levels, and normalizing redox signaling and its downstream components, including Nrf2, HO-1, and SOD2, as well as glial cell activation markers, such as Iba-1 and GFAP. Further, ibrutinib treatment inhibited LPS-activated inflammasome activation by targeting NLRP3/P38/Caspase-1 signaling. Interestingly, LPS reduced the number of dendritic spines and expression of BDNF, and synaptic-related markers, including PSD95, snap25, and synaptophysin, were improved by ibrutinib treatment in the hippocampal area of the mouse brain. In conclusion, our findings suggest that ibrutinib can alleviate neuroinflammation and synaptic defects, suggesting it has antidepressant potential against LPS-induced neuroinflammation and depression.